SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio announced positive Phase 3 PROPEL 3 results for oral…

BridgeBio Pharma, Inc. · PRESS-RELEASE filed Jun 28, 2026 at 16:00 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Jun 28, 2026 at 16:00 ET

BridgeBio announced positive Phase 3 PROPEL 3 results for oral infigratinib in achondroplasia, published in NEJM and presented at ICCBH. The drug met primary and key secondary endpoints with the largest annualized height velocity improvement in any Phase 3 achondroplasia study and first statistically significant body proportionality improvement. NDA submission to FDA is planned for Q3 2026 with US launch anticipated in early to mid 2027.

  • Phase 3 PROPEL 3 met primary endpoint: LS mean treatment difference in annualized height velocity +1.74 cm/yr (p<0.0001); observed mean difference +2.10 cm/yr
  • Key secondary endpoint met: height Z-score LS mean increase +0.41 SD (p<0.0001)
  • First statistically significant body proportionality improvement in achondroplasia: LS mean treatment difference -0.05 (p<0.05) in children <8 years
  • New arm span Z-score data: LS mean +0.37 SD vs placebo (p<0.0001), first statistically significant result in a placebo-controlled achondroplasia trial

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access